ORIGYN Foundation Receives Strategic Investment of $20M from World-Renowned Investors, including Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko and Vectr Ventures
23.11.2021 17:38:00 EET | Business Wire | Press release
ORIGYN Foundation, the Swiss nonprofit dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has today announced a strategic raise of $20 million. Investors in this round include Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko, Vectr Ventures, Carter Reum, Div Turakhia, GD10 Ventures and more. Ahead of the foundation’s public token release, this private round now values ORIGYN at $300 million.
“We’re incredibly fortunate and excited to include so many influential names in this funding round. ORIGYN is unique in what it brings to this world. It’s a sign of support for what ORIGYN is trying to achieve—using technology to solve for identity, authenticity and proof of ownership. Our partners have seen the opportunity we provide to unlock value for owners and creators,” said Daniel Haudenschild, CEO of ORIGYN Entreprise SA, which is the operating entity of ORIGYN Foundation.
Founded in October of 2020, ORIGYN is led by its founding partners and council members Gian Bochsler, Vincent Perriard and Mike Schwartz, as well as by CEO Daniel Haudenschild. The foundation’s technology certifies and guarantees the authenticity of physical and digital items using advanced recognition and identification techniques created by leading experts in computer vision, artificial intelligence and decentralized infrastructure. It also unites the greatest contemporary players across select industries to protect, celebrate, elevate and reward creativity through its novel approach to NFTs.
ORIGYN currently operates the following industry verticals:
● ORIGYN Art is an exclusive community for the fine art market on the blockchain. This vertical establishes a connection between physical works of art and NFT certificates to create the ultimate marketplace experience for creators, industry professionals, collectors and enthusiasts.
● ORIGYN Collectibles is a revolutionary platform designed to empower individuals with shared passions to buy, sell, trade and experience collectors’ items. This vertical rewards and celebrates creativity by tokenizing certificates of ownership that verify the uniqueness and authenticity of physical collectibles.
● ORIGYN Digital Media is a comprehensive ecosystem built for media creators of all types to activate their social capital. This vertical provides tooling for all forms of experiential content, artifacts and marketplaces for the world’s most creative icons and their fans.
● ORIGYN Luxury is the only digital certification solution guaranteed to prove authenticity using a luxury object’s own biometric features. These digital certificates increase trust between companies and their clients with a paperless solution, guaranteed by ORIGYN, which facilitates the resale of the object. This vertical brings NFTs to life by enabling the object itself to become its own proof of authenticity.
Funding from this round powers the foundation’s mission and contributes to the expansion and continuous improvement of ORIGYN’s verticals as directed by governing token holders. Additionally, it will be used to fund ongoing R&D and onboard the foundation’s growing list of industry partners to the ecosystem.
The ORIGYN authentication platform far surpasses other NFT certification solutions in the market today due to the unique biometric and ownership data included in ORIGYN digital twins, as well as the global guarantee that backs every digital certificate. ORIGYN will officially launch these digital certificates across industry verticals during the first half of 2022. The foundation’s utility token, OGY, will also become publicly tradable in 2022. OGY is necessary to engage with the core services of the platform and is used to create and transact certificates of authenticity.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. For more information, visit origyn.ch.
ORIGYN Foundation: Website Twitter LinkedIn Facebook Medium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005882/en/
Contact information
Seamus Conwell
seamus.conwell@150bond.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
